AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

• Published in: Journal of Alzheimer's disease Vol. 55; no. 3; p. 1039
• Main Authors: Cebers, Gvido, Alexander, Robert C, Haeberlein, Samantha Budd, Han, David, Goldwater, Ronald, Ereshefsky, Larry, Olsson, Tina, Ye, Naidong, Rosen, Laura, Russell, Muir, Maltby, Justine, Eketjäll, Susanna, Kugler, Alan R
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2017
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - blood; Amyloid beta-Peptides - cerebrospinal fluid; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Food; Healthy Volunteers; Humans; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Male; Middle Aged; Neurologic Examination; Peptide Fragments - blood; Peptide Fragments - cerebrospinal fluid; Spiro Compounds - pharmacokinetics; Spiro Compounds - therapeutic use; Time Factors; Young Adult; Phase I clinical trials; early onset Alzheimer’s disease; pharmacodynamics; pharmacokinetics; AZD3293; BACE1 protein-human; Amyloid-beta peptides; cerebrospinal fluid proteins

AZD3293 (LY3314814) is a promising new potentially disease-modifying BACE1 (β-secretase) inhibitor in Phase III clinical development for the treatment of Alzheimer's disease. Reported here are the first two Phase I studies: (1) a single ascending dose study evaluating doses of 1-750 mg with a f...